Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease

MT Newswires Live

Apr 29, 2025

Cullinan Therapeutics (CGEM) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.

The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.

The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.

The company said it expects to start the study in Q2.

Shares of Cullinan were up 2.4% in recent trading.

Price: 7.94, Change: +0.19, Percent Change: +2.39

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531606754"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531606754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531606754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 22:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531606754","market":"nz","top_or_hot":-1,"title":"Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> (CGEM) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.</p><p>The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.</p><p>The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.</p><p>The company said it expects to start the study in Q2.</p><p>Shares of Cullinan were up 2.4% in recent trading.</p><p>Price: 7.94, Change: +0.19, Percent Change: +2.39</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-29 22:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> (CGEM) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.</p><p>The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.</p><p>The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.</p><p>The company said it expects to start the study in Q2.</p><p>Shares of Cullinan were up 2.4% in recent trading.</p><p>Price: 7.94, Change: +0.19, Percent Change: +2.39</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2531606754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531606754","pubTimestamp":1745938754,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cullinan Therapeutics  said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.The company said it expects to start the study in Q2.Shares of Cullinan were up 2.4% in recent trading.Price: 7.94, Change: +0.19, Percent Change: +2.39","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","BK4139":"生物科技"},"translate_title":"Cullinan Therapeutics将在美国启动CLN-978治疗中度至重度干燥症的研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":1},"content_text":"Cullinan Therapeutics (CGEM) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.The company said it expects to start the study in Q2.Shares of Cullinan were up 2.4% in recent trading.Price: 7.94, Change: +0.19, Percent Change: +2.39","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}